These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 20415601)

  • 41. [Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors].
    Porst H
    Urologe A; 2004 Jul; 43(7):820-8. PubMed ID: 15197447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
    Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
    J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Current role of sildenafil in the management of erectile dysfunction].
    Akhvlediani ND; Matyukhov IP
    Urologiia; 2018 May; (2):142-146. PubMed ID: 29901310
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of CPAP and PDE5i on erectile function in men with obstructive sleep apnea and erectile dysfunction: A systematic review and meta-analysis.
    Li Z; Fang Z; Xing N; Zhu S; Fan Y
    Sleep Med Rev; 2019 Dec; 48():101217. PubMed ID: 31715462
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multicenter, double-blind, placebo-controlled study of sildenafil citrate in Canadian men with erectile dysfunction and untreated symptoms of depression, in the absence of major depressive disorder.
    Kennedy SH; Dugré H; Defoy I
    Int Clin Psychopharmacol; 2011 May; 26(3):151-8. PubMed ID: 21471773
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Centrally acting mechanisms for the treatment of male sexual dysfunction.
    Miner MM; Seftel AD
    Urol Clin North Am; 2007 Nov; 34(4):483-96, v. PubMed ID: 17983889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies.
    Porst H; Gacci M; Büttner H; Henneges C; Boess F
    Eur Urol; 2014 Feb; 65(2):455-64. PubMed ID: 24119319
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
    Shkolyar E; Li S; Tang J; Eisenberg ML
    J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction.
    Andersson KE
    Pharmacol Rev; 2011 Dec; 63(4):811-59. PubMed ID: 21880989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.
    Hong JH; Kwon YS; Kim IY
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):183-192. PubMed ID: 27690667
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety of Phosphodiesterase-5 Inhibitors in Valvular Heart Disease.
    Gopal A; Sharma T; Calkins JB
    J Cardiovasc Pharmacol; 2021 Sep; 78(3):372-376. PubMed ID: 34074904
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double-blind, placebo-controlled study.
    Ortaç M; Çayan S; Çalişkan MK; Yaman MÖ; Okutucu TM; Semerci MB; Altay AB; Balbay MD; Özcan MF; Kadioğlu A
    Andrology; 2013 Jul; 1(4):549-55. PubMed ID: 23785019
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.
    Lee M; Sharifi R
    Drugs Aging; 2018 Mar; 35(3):175-187. PubMed ID: 29464656
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and Safety of Sildenafil in Men With Sexual Dysfunction and Spinal Cord Injury.
    Ohl DA; Carlsson M; Stecher VJ; Rippon GA
    Sex Med Rev; 2017 Oct; 5(4):521-528. PubMed ID: 28341580
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
    Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
    J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Avanafil for the treatment of erectile dysfunction.
    Zurawin JL; Stewart CA; Anaissie JE; Yafi FA; Hellstrom WJ
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1163-70. PubMed ID: 27416913
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of Dopaminergic Pathways to Treat Erectile Dysfunction.
    Simonsen U; Comerma-Steffensen S; Andersson KE
    Basic Clin Pharmacol Toxicol; 2016 Oct; 119 Suppl 3():63-74. PubMed ID: 27541930
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Avanafil for the treatment of erectile dysfunction.
    Segal R; Burnett AL
    Drugs Today (Barc); 2012 Jan; 48(1):7-15. PubMed ID: 22384456
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
    Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
    J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploring the association between erectile rigidity and treatment adherence with sildenafil.
    Mazzola CR; Deveci S; Teloken P; Mulhall JP
    J Sex Med; 2013 Jul; 10(7):1861-6. PubMed ID: 23253943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.